Prof Tiziano Barbui speaks to ecancer in an online interview for the virtual EHA 2020 meeting.
He outlines the background, design and results of this phase II randomised trial (LOW-PV), which is comparing ropeginterferon versus phlebotomy in low-risk patients with polycythemia vera.
Prof Barbui concludes that ropeginterferon is safe and effective in the haematocrit on target in low-risk patients with polycythemia vera.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
